IP Library Granted Patent US 6,914,055
Granted Patent B2
US 6,914,055 · App. 10/649,130 · Granted Jul 5, 2005

Delivery of a therapeutic agent in a formulation for reduced toxicity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,914,055
App. No.
10/649,130
Granted
Jul 5, 2005
Kind
B2
Abstract

Methods and compositions for reducing toxicity of a toxic agent are provided in which a polysaccharide, galactomannan is coadministered with a therapeutic agent in a liquid formulation to a subject to reduce toxicity of the agent for the subject.

Claims (10)

1. A cancer therapeutic formulation having reduced toxicity, comprising, an effective dose of a galactomannan, and an effective dose of a chemotherapeutic agent in a mixture.

2. A cancer therapeutic formulation according to claim 1 wherein the formulation is in a powder form.

3. A cancer therapeutic formulation according to claim 1 wherein the formulation is in a liquid form.

4. A pharmaceutical formulation, comprising: a mixture of galactomannan polysaccharide and an effective dose for treating cancer of a chemotherapeutic agent in a pharmaceutically acceptable formulation.

5. The pharmaceutical formulation of claim 4 , wherein the mixture comprises an amount of galactomannan and the chemotherapeutic agent in the ratio suitable for reducing a toxic effect in the subject, the toxic effect resulting from administration of a cancer treating amount of chemotherapeutic agent absent galactomannan.

6. The pharmaceutical formulation of claim 4 , wherein the mixture comprises an amount of galactomannan and the chemotherapeutic agent in a ratio suitable for enhancing efficacy of chemotherapeutic effect for treating the cancer.

7. The pharmaceutical formulation of claim 4 , wherein the chemotherapeutic agent is 5-FU.

8. The pharmaceutical formulation of claim 4 , wherein the chemotherapeutic agent is adriamycin.

9. The formulation of claim 5 or 6 , wherein the formulation is in a powder form.

10. The formulation of claim 5 or 6 , wherein the formulation is in a liquid form.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Sep 17, 2019
From: 10X FUND L.P.
To: GALECTIN THERAPEUTICS, INC.
Reel/Frame 050399/0679 →
CHANGE OF NAME Recorded Oct 18, 2012
From: PRO-PHARMACEUTICALS, INC.
To: GALECTIN THERAPEUTICS INC.
Reel/Frame 029150/0654 →
SECURITY AGREEMENT Recorded Aug 26, 2009
From: PRO-PHARMACEUTICALS, INC.
To: 10X FUND, LP
Reel/Frame 023134/0968 →
CHANGE OF NAME Recorded Jun 4, 2007
From: MARLBOROUGH RESEARCH AND DEVELOPMENT, INC.
To: PROSPECT PHARMACEUTICALS, INC.
Reel/Frame 019365/0633 →
CHANGE OF NAME Recorded Jun 4, 2007
From: PROSPECT PHARMACEUTICALS, INC.
To: PROSPECT THERAPEUTICS, INC.
Reel/Frame 019365/0638 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2007
From: PLATT, DAVID
To: GLYCOGENESYS, INC.
Reel/Frame 019375/0493 →
COURT APPOINTMENT OF TRUSTEE Recorded Jun 4, 2007
From: GLYCOGENESYS, INC.
To: MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF GLYCOGENESYS, INC.
Reel/Frame 019365/0501 →
ASSIGNMENT OF CLAIMS Recorded Jun 4, 2007
From: MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF GLYCOGENESYS, INC.
To: MARLBOROUGH RESEARCH AND DEVELOPMENT, INC.
Reel/Frame 019365/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2007
From: KLYOSOV, ANATOLE, DR.; PLATT, DAVID, DR.
To: PRO-PHARMACEUTICALS, INC.
Reel/Frame 018942/0833 →